Compare Adecoagro SA (AGRO) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adecoagro SA vs Alnylam Pharmaceuticals, Inc. — how do they compare? Adecoagro SA trades at $9.24 (market cap $1.36B), while Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 21.8× Adecoagro SA's market cap, and Adecoagro SA pays a 3.15% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| AGRO | ALNY | |
|---|---|---|
Market Cap | $1.36B | $29.60B |
Sector | Technology | Health |
52-Week High | $15.25 | $491.22 |
52-Week Low | $7.13 | $205.48 |
Enterprise Value | $3.39B | $27.56B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGRO trades at $9.34, down 3.31% today, with a bearish technical signal from moving averages. The company reported mixed earnings, beating in Q3 2025 but missing in the last three quarters. Recent news highlights record adjusted EBITDA in Q2 2026 and an acquisition to expand operations. Valuation ratios like P/S of 0.71 and P/B of 0.77 suggest potential undervaluation, but low net income margins and negative recent EPS pose challenges.
The outlook is cautious; analyst consensus is mixed with 37.5% buy ratings. Upside potential exists from operational expansions and cost management, but risks include earnings volatility, high leverage from acquisitions, and commodity price exposure. Investors should weigh the low valuation against inconsistent profitability and macroeconomic headwinds.
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adecoagro SA
Adecoagro is a South American agricultural company. It operates a diversified business including farming crops, rice, and dairy, as well as producing sugar, ethanol, and renewable energy from its industrial facilities.
Read more on AGRO →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
